Both sides of RFK Jr.'s peptide policy face legal risks

“Illegal” is doing too much work in the peptide fight. Any legal analysis of RFK Jr.’s peptide policy has to separate at least three questions that have been run together in public debate: whether FDA had statutory authority over compounded peptides, whether its 2023 process was procedurally vulnerable, and whether the current administration can unwind that position without building a record that survives Administrative Procedure Act review.

The narrow correction comes first. FDA’s 2023 Category 2 treatment of the disputed peptides was an interim categorization under agency guidance, not a final rulemaking; and the 19 peptides now described as being “restored” had not previously been on Category 1 for ordinary Section 503A compounding in the first place.[1][2] That does not make FDA’s 2023 posture immune from challenge. It does make the phrase “illegally reclassified” a poor legal description.

What the 2023 action was, and what it was not

Category labels matter because they tell counsel what kind of challenge is available. A final rule invites one set of arguments. Guidance, interim enforcement categorization, and agency list management invite others. When a public official calls the 2023 action “illegal,” the word can sound as if a court has already found FDA exceeded the Federal Food, Drug, and Cosmetic Act. The available record does not support that.

The stronger critique of FDA’s 2023 posture is narrower and more technical: compounders could argue that FDA used an opaque interim process with serious practical consequences, giving the regulated community too little visibility into the evidence and reasoning behind Category 2 placement. That is a procedural and administrative-record argument. It is not the same thing as saying FDA had no jurisdiction over bulk drug substances used in traditional compounding.

This distinction is not academic for pharmacies, telehealth platforms, and investors. If the theory is “FDA had no power,” business risk looks one way. If the theory is “FDA had power but may have exercised it through a procedurally vulnerable interim mechanism,” the risk looks different: more dependent on timing, final agency action, exhaustion, remedy, and the contents of the administrative record.

The Evexias/Farmakeio case shows the real pressure point

The Evexias/Farmakeio litigation is the most useful lens because it did not need the exaggerated claim that FDA simply acted outside the law. The plaintiffs challenged the transparency and procedure behind FDA’s treatment of certain peptides, including objections to how FDA reached and communicated its position. The settlement announced in 2024 did not say FDA confessed illegality; it provided for administrative closure while FDA moved toward a final rule, with a March 14, 2027 deadline referenced in the settlement framework.[3][4]

That posture matters. Administrative closure pending final rulemaking is not a merits judgment that the 2023 action was ultra vires. It is a litigation-management result that leaves both sides with usable talking points and neither side with a clean judgment. Compounders can say FDA was pushed toward a more formal process. FDA can say it preserved its authority and did not admit the prior categorization was unlawful.

A court reviewing the issue would not ask whether peptide access is politically attractive or whether patients are sincere in wanting these products. It would ask whether there is final agency action, whether the challengers are within the zone of interests, whether FDA has statutory authority, whether the agency adequately explained itself, and whether any procedural defect was prejudicial. Those questions do not collapse into a single label.

Nor does Thompson v. Western States Medical Center, 535 U.S. 357 (2002), do the work that some peptide-access advocates ask of it. Thompson is an important boundary marker: FDA’s regulation of compounding is not unlimited, and the Supreme Court rejected particular advertising restrictions on First Amendment grounds. But Thompson did not hold that compounded drugs sit outside FDA’s jurisdiction or that the agency cannot evaluate bulk substances used by Section 503A pharmacies.

The old restriction had vulnerabilities, but not the one RFK Jr. keeps naming

The best challenge to the 2023 posture sounds in administrative regularity. Did FDA give enough notice of the evidence it relied on? Did it explain why the substances belonged in Category 2? Did the interim guidance operate like a binding rule while avoiding the procedures normally attached to rulemaking? Those are serious questions because regulated parties often change behavior in response to “interim” agency documents that are practically difficult to ignore.

But those questions do not become stronger when translated into a broad claim that FDA “illegally reclassified” peptides that had previously been approved for 503A compounding. The factual premise is wrong as to the 19 peptides: they had not been Category 1 substances before the 2023 Category 2 treatment.[2] If a pharmacy’s compliance memo starts from a restoration narrative, it is starting from the wrong box on the chart.

There is also a remedy problem hidden inside the rhetoric. If the defect was insufficient process, the ordinary administrative-law remedy is not necessarily permanent access to the substances. It may be a remand, a better explanation, a more formal rulemaking process, or a temporary change in enforcement posture while the agency repairs the record. A procedural victory can be commercially valuable. It is still not the same thing as a statutory entitlement to compound the substances indefinitely.

The reversal has its own administrative-law problem

Stopping after correcting RFK Jr.’s legal label would miss the more current risk. The administration’s move toward reversal may be vulnerable from the opposite direction: not because peptide deregulation is categorically forbidden, but because the process now unfolding may give public-health challengers an APA theory of their own.

The advisory-committee sequence is the part that deserves slow reading. As of April 2026, only 3 of the 12 authorized voting seats on the Pharmacy Compounding Advisory Committee were filled, and 9 new members with reported peptide-industry ties were appointed before the July meeting.[5] That fact alone does not prove a legal defect. Advisory committees often change membership across administrations, and expertise can overlap with industry experience. The legal question is whether FDA can later rely on the committee’s recommendation without adequately addressing the appearance and substance of non-independence.

That issue becomes sharper because the committee process appears to be moving faster than the science record changed. The July 23-24, 2026 meeting occurred only days before the current date, and the reported vote was 8-6-1.[6] A close and recent vote is not automatically suspect. But if FDA treats it as a decisive answer while brushing past contrary staff findings, the agency will have created the kind of seam APA litigants know how to pull.

Staff science is not binding, but it cannot be ignored

The staff findings reported around the meeting are not trivial. FDA staff found no adequate human data for any of the seven peptides under review; TB-500 and KPV had zero human administration studies, MOTS-c had no published human trials, and the BPC-157 record was described as consisting of five studies of short duration and small sample sizes.[8] That is not a medical conclusion that every product is unsafe in every circumstance. It is an administrative-record problem for an agency that may now decide to expand access.

An agency may disagree with its staff. It may change policy. It may assign different weight to uncertainty, patient access, compounding practice, and enforcement priorities. What it may not do safely, under the APA, is announce a result that depends on a committee recommendation while failing to explain why the committee’s view deserves more weight than the staff’s assessment of limited or absent human data.

That is where the current administration’s legal exposure differs from the 2023 exposure. The earlier FDA action was vulnerable to arguments that an interim process carried too much practical force without enough procedural transparency. The reversal is vulnerable to arguments that the agency is letting a newly constituted advisory body supply the policy answer without a reasoned reconciliation of the science record.

Section 503A(c) is a procedural risk, not a magic wand

Section 503A(c) gives the HHS Secretary a bypass route around PCAC consultation only “if necessary to protect the public health.” The phrase is not decorative. It ties the bypass to necessity and public-health protection, not simply to a policy preference for faster access. Commentary on the current peptide fight has treated the provision as a possible way to move without waiting on the ordinary advisory process, but using it to expand access rather than to remove or restrict a perceived danger would be novel and legally untested.[4]

The risk is not that a court would necessarily reject that use on sight. The statute does not come with a bright-line judicial holding, on the present materials, that confines it to emergency removals. The risk is that the administration would need to explain why bypassing consultation is necessary to protect public health when the practical effect is to permit broader compounding of substances for which FDA staff have identified limited human evidence.

That explanation would have to do more than invoke patient access in general terms. It would need to confront the statutory word “necessary,” the staff record, the reason for accelerating the process, and the relationship between access expansion and public-health protection. A thin explanation would invite a challenger to argue that the agency used an emergency-style bypass for a deregulatory objective that Congress did not clearly authorize.

What an APA challenge to the reversal would look like

The likely public-health challenge would not need to prove that every peptide at issue is dangerous. It would more plausibly argue that FDA acted arbitrarily and capriciously by relying on a compromised or insufficiently independent advisory process, failing to respond to its own staff’s scientific concerns, and inadequately explaining a sharp change from the 2023 risk posture.

Public-health groups are already speaking in terms that point toward the drug-approval system rather than only toward individual peptide safety. CSPI’s Dr. Peter Lurie described the policy as a “profound threat” to the drug approval system.[7] That kind of framing matters because an APA plaintiff must translate disagreement into a reviewable agency defect. “The agency weakened the approval system without a reasoned explanation” is a more legally useful theory than “we dislike peptides.”

Standing and ripeness would still require work. A public-health organization would have to identify a cognizable injury and an agency action ready for review. If FDA has not yet issued a final rule or definitive action, challengers may face timing problems. If the agency proceeds through final rulemaking, the dispute becomes cleaner, but FDA also gets an opportunity to repair the record.

For regulated businesses, the practical consequence is that a favorable signal from HHS or PCAC should not be treated as litigation closure. Pharmacies and platforms can gain commercial room from agency movement long before the legal risk is settled. That same gap can become costly if contracts, marketing, prescribing workflows, and supply arrangements assume that reversal equals final legal security.

The compliance question is not who won the politics

Counsel assessing exposure should keep the boxes separate. The 2023 FDA posture can be attacked as procedurally underdeveloped without accepting the claim that the agency had no authority. The 2026 reversal can be welcomed commercially while still presenting APA risk if FDA leans too heavily on a newly reshaped committee or invokes Section 503A(c) in a way that outruns the statutory explanation.

The cleanest legal statement is also the least satisfying one for partisans: RFK Jr.’s “illegal reclassification” label is inaccurate on the present record, but the administration’s own reversal strategy may supply opponents with a different APA case. The old restriction was not legally bulletproof. The new deregulation is not either.

References

1. What FDA’s Latest Peptide Action Really Means for Compounding Pharmacies, Buchanan Ingersoll & Rooney
2. FDA Peptide Regulation & RFK Announcement: What Compounding Pharmacies Need to Know, Frier Levitt
3. Settlement Reached in Evexias Suit Against FDA, Alliance for Pharmacy Compounding, September 2024
4. FDA’s Peptide Rally: What Compounders and Industry Need to Know Post 1 of 2, FDA Law Blog, April 2026
5. RFK Jr. wants to make it easier to get peptides. FDA scientists disagree, NBC News
6. Peptides, FDA, Kennedy, injection, BPC-157, AP News
7. Peptides, FDA panel, compounding, RFK, NPR, June 30, 2026
8. WATCH LIVE: FDA advisory panel considers use of peptides, PBS NewsHour